Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Risico op kanker na gebruik NDMA-gecontamineerd valsartan
nov 2018
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
okt 2021 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
mrt 2024
nov 2023
sep 2023